Patent · US Expired

Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione

US7208516B2 · kind B2 · utility

27Cited by

46References

18Claims

0Family size

Assignee

CELGENE CORPORATION · US

Inventors

George W. Muller · Northbrook, US
Peter Schafer · Ottersheim, DE
Patricia Rohane · Florham Park, US

Key dates

Filing date	Mar 28, 2006
Grant date	Apr 24, 2007
Priority date	—
Expiry date	Mar 28, 2026

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/4035
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods of treating, managing or preventing psoriatic arthritis are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione alone or in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.